{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:37:21Z","timestamp":1773823041372,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["133063-PF-19-102-01-CPPB"],"award-info":[{"award-number":["133063-PF-19-102-01-CPPB"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000936","name":"Gordon and Betty Moore Foundation","doi-asserted-by":"publisher","award":["GBMF7853"],"award-info":[{"award-number":["GBMF7853"]}],"id":[{"id":"10.13039\/100000936","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Friends of Dana Farber"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s10689-021-00240-6","type":"journal-article","created":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T03:02:57Z","timestamp":1615345377000},"page":"35-47","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Knowledge and psychosocial impact of genetic counseling and multigene panel testing among individuals with ovarian cancer"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5033-5701","authenticated-orcid":false,"given":"Rachel A.","family":"Pozzar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangxin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niya","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill E.","family":"Stopfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manan M.","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghan","family":"Underhill-Blazey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,10]]},"reference":[{"issue":"3","key":"240_CR1","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","volume":"20","author":"KP Pennington","year":"2014","unstructured":"Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, Thornton A, Norquist BM, Casadei S, Nord AS, Agnew KJ, Pritchard CC, Scroggins S, Garcia RL, King MC, Swisher EM (2014) Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 20(3):764\u2013775. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2287","journal-title":"Clin Cancer Res"},{"issue":"44","key":"240_CR2","doi-asserted-by":"publisher","first-page":"18032","DOI":"10.1073\/pnas.1115052108","volume":"108","author":"T Walsh","year":"2011","unstructured":"Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, Roeb W, Agnew KJ, Stray SM, Wickramanayake A, Norquist B, Pennington KP, Garcia RL, King MC, Swisher EM (2011) Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 108(44):18032\u201318037. https:\/\/doi.org\/10.1073\/pnas.1115052108","journal-title":"Proc Natl Acad Sci USA"},{"issue":"21","key":"240_CR3","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","volume":"30","author":"K Alsop","year":"2012","unstructured":"Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30(21):2654\u20132663. https:\/\/doi.org\/10.1200\/JCO.2011.39.8545","journal-title":"J Clin Oncol"},{"issue":"1","key":"240_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ygyno.2014.09.009","volume":"136","author":"JM Lancaster","year":"2015","unstructured":"Lancaster JM, Powell CB, Chen LM, Richardson DL, Committee SGOCP (2015) Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 136(1):3\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2014.09.009","journal-title":"Gynecol Oncol"},{"key":"240_CR5","unstructured":"National Comprehensive Cancer Network (2020) Genetic\/familial high-risk assessment: breast and ovarian: National Comprehensive Cancer Network. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf."},{"key":"240_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.breast.2019.01.002","volume":"45","author":"C Colas","year":"2019","unstructured":"Colas C, Golmard L, de Pauw A, Caputo SM, Stoppa-Lyonnet D (2019) Decoding hereditary breast cancer: benefits and questions from multigene panel testing. Breast 45:29\u201335. https:\/\/doi.org\/10.1016\/j.breast.2019.01.002","journal-title":"Breast"},{"key":"240_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2019-106739","author":"H Song","year":"2020","unstructured":"Song H, Dicks EM, Tyrer J, Intermaggio M, Chenevix-Trench G, Bowtell DD, Traficante N, Group A, Brenton J, Goranova T, Hosking K, Piskorz A, van Oudenhove E, Doherty J, Harris HR, Rossing MA, Duerst M, Dork T, Bogdanova NV, Modugno F, Moysich K, Odunsi K, Ness R, Karlan BY, Lester J, Jensen A, Kr\u00fcger Kjaer S, H\u00f8gdall E, Campbell IG, L\u00e1zaro C, Pujara MA, Cunningham J, Vierkant R, Winham SJ, Hildebrandt M, Huff C, Li D, Wu X, Yu Y, Permuth JB, Levine DA, Schildkraut JM, Riggan MJ, Berchuck A, Webb PM, Group OS, Cybulski C, Gronwald J, Jakubowska A, Lubinski J, Alsop J, Harrington P, Chan I, Menon U, Pearce CL, Wu AH, de Fazio A, Kennedy CJ, Goode E, Ramus S, Gayther S, Pharoah P (2020) Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer. J Med Genet. https:\/\/doi.org\/10.1136\/jmedgenet-2019-106739","journal-title":"J Med Genet"},{"issue":"7","key":"240_CR8","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1200\/JCO.19.01907","volume":"38","author":"X Yang","year":"2019","unstructured":"Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, Dunning AM, Redman J, Scarth J, Plaskocinska I, Luccarini C, Shah M, Pooley K, Dorling L, Lee A, Adank MA, Adlard J, Aittom\u00e4ki K, Andrulis IL, Ang P, Barwell J, Bernstein JL, Bobolis K, Borg \u00c5, Blomqvist C, Claes KBM, Concannon P, Cuggia A, Culver JO, Damiola F, de Pauw A, Diez O, Dolinsky JS, Domchek SM, Engel C, Evans DG, Fostira F, Garber J, Golmard L, Goode EL, Gruber SB, Hahnen E, Hake C, Heikkinen T, Hurley JE, Janavicius R, Kleibl Z, Kleiblova P, Konstantopoulou I, Kvist A, Laduca H, Lee ASG, Lesueur F, Maher ER, Mannermaa A, Manoukian S, McFarland R, McKinnon W, Meindl A, Metcalfe K, Mohd Taib NA, Moilanen J, Nathanson KL, Neuhausen S, Ng PS, Nguyen-Dumont T, Nielsen SM, Obermair F, Offit K, Olopade OI, Ottini L, Penkert J, Pylk\u00e4s K, Radice P, Ramus SJ, Rudaitis V, Side L, Silva-Smith R, Silvestri V, Skytte A-B, Slavin T, Soukupova J, Tondini C, Trainer AH, Unzeitig G, Usha L, van Overeem HT, Whitworth J, Wood M, Yip CH, Yoon S-Y, Yussuf A, Zogopoulos G, Goldgar D, Hopper JL, Chenevix-Trench G, Pharoah P, George SHL, Balma\u00f1a J, Houdayer C, James P, El-Haffaf Z, Ehrencrona H, Janatova M, Peterlongo P, Nevanlinna H, Schmutzler R, Teo S-H, Robson M, Pal T, Couch F, Weitzel JN, Elliott A, Southey M, Winqvist R, Easton DF, Foulkes WD, Antoniou AC, Tischkowitz M (2019) Cancer risks associated with germline PALB2 pathogenic variants: An international study of 524 families. J Clin Oncol 38(7):674\u2013685. https:\/\/doi.org\/10.1200\/JCO.19.01907","journal-title":"J Clin Oncol"},{"issue":"3","key":"240_CR9","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/cncr.32572","volume":"126","author":"V Vysotskaia","year":"2020","unstructured":"Vysotskaia V, Kaseniit KE, Bucheit L, Ready K, Price K, Johansen Taber K (2020) Clinical utility of hereditary cancer panel testing: impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations. Cancer 126(3):549\u2013558. https:\/\/doi.org\/10.1002\/cncr.32572","journal-title":"Cancer"},{"key":"240_CR10","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00199","author":"MJ Hall","year":"2018","unstructured":"Hall MJ, Patrick-Miller LJ, Egleston BL, Domchek SM, Daly MB, Ganschow P, Grana G, Olopade OI, Fetzer D, Brandt A, Chambers R, Clark DF, Forman A, Gaber R, Gulden C, Horte J, Long JM, Lucas T, Madaan S, Mattie K, McKenna D, Montgomery S, Nielsen S, Powers J, Rainey K, Rybak C, Savage M, Seelaus C, Stoll J, Stopfer JE, Yao XS, Bradbury AR (2018) Use and patient-reported outcomes of clinical multigene panel testing for cancer susceptibility in the multicenter communication of genetic test results by telephone study. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO.18.00199","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"240_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10549-016-4003-9","volume":"160","author":"R Graffeo","year":"2016","unstructured":"Graffeo R, Livraghi L, Pagani O, Goldhirsch A, Partridge AH, Garber JE (2016) Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. Breast Cancer Res Treat 160(3):393\u2013410. https:\/\/doi.org\/10.1007\/s10549-016-4003-9","journal-title":"Breast Cancer Res Treat"},{"issue":"6349","key":"240_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA Jr (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357(6349):409\u2013413. https:\/\/doi.org\/10.1126\/science.aan6733","journal-title":"Science"},{"issue":"4","key":"240_CR13","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1037\/a0014778","volume":"28","author":"JG Hamilton","year":"2009","unstructured":"Hamilton JG, Lobel M, Moyer A (2009) Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review. Health Psychol 28(4):510\u2013518. https:\/\/doi.org\/10.1037\/a0014778","journal-title":"Health Psychol"},{"issue":"2","key":"240_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/cncr.20363","volume":"101","author":"Y Murakami","year":"2004","unstructured":"Murakami Y, Okamura H, Sugano K, Yoshida T, Kazuma K, Akechi T, Uchitomi Y (2004) Psychologic distress after disclosure of genetic test results regarding hereditary nonpolyposis colorectal carcinoma: a preliminary report. Cancer 101(2):395\u2013403. https:\/\/doi.org\/10.1002\/cncr.20363","journal-title":"Cancer"},{"issue":"1","key":"240_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejca.2006.08.023","volume":"43","author":"I van Oostrom","year":"2007","unstructured":"van Oostrom I, Meijers-Heijboer H, Duivenvoorden HJ, Br\u00f6cker-Vriends AHJT, van Asperen CJ, Sijmons RH, Seynaeve C, Van Gool AR, Klijn JGM, Tibben A (2007) Prognostic factors for hereditary cancer distress six months after BRCA1\/2 or HNPCC genetic susceptibility testing. Eur J Cancer 43(1):71\u201377. https:\/\/doi.org\/10.1016\/j.ejca.2006.08.023","journal-title":"Eur J Cancer"},{"issue":"1","key":"240_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10897-017-0135-2","volume":"27","author":"MI Liang","year":"2018","unstructured":"Liang MI, Wong DH, Walsh CS, Farias-Eisner R, Cohen JG (2018) Cancer genetic counseling and testing: perspectives of epithelial ovarian cancer patients and gynecologic oncology healthcare providers. J Genet Couns 27(1):177\u2013186. https:\/\/doi.org\/10.1007\/s10897-017-0135-2","journal-title":"J Genet Couns"},{"issue":"5","key":"240_CR17","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1007\/s10897-017-0090-y","volume":"26","author":"HS Lumish","year":"2017","unstructured":"Lumish HS, Steinfeld H, Koval C, Russo D, Levinson E, Wynn J, Duong J, Chung WK (2017) Impact of panel gene testing for hereditary breast and ovarian cancer on patients. J Genet Couns 26(5):1116\u20131129. https:\/\/doi.org\/10.1007\/s10897-017-0090-y","journal-title":"J Genet Couns"},{"issue":"10","key":"240_CR18","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1016\/j.pec.2017.05.031","volume":"100","author":"H Faller","year":"2017","unstructured":"Faller H, Brahler E, Harter M, Keller M, Schulz H, Wegscheider K, Weis J, Boehncke A, Reuter K, Richard M, Sehner S, Koch U, Mehnert A (2017) Unmet needs for information and psychosocial support in relation to quality of life and emotional distress: a comparison between gynecological and breast cancer patients. Patient Educ Couns 100(10):1934\u20131942. https:\/\/doi.org\/10.1016\/j.pec.2017.05.031","journal-title":"Patient Educ Couns"},{"issue":"10","key":"240_CR19","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1245\/s10434-015-4754-2","volume":"22","author":"NS Kapoor","year":"2015","unstructured":"Kapoor NS, Curcio LD, Blakemore CA, Bremner AK, McFarland RE, West JG, Banks KC (2015) Multigene panel testing detects equal rates of pathogenic BRCA1\/2 mutations and has a higher diagnostic yield compared to limited BRCA1\/2 analysis alone in patients at risk for hereditary breast cancer. Ann Surg Oncol 22(10):3282\u20133288. https:\/\/doi.org\/10.1245\/s10434-015-4754-2","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"240_CR20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s10689-013-9609-z","volume":"12","author":"SV Montgomery","year":"2013","unstructured":"Montgomery SV, Barsevick AM, Egleston BL, Bingler R, Ruth K, Miller SM, Malick J, Cescon TP, Daly MB (2013) Preparing individuals to communicate genetic test results to their relatives: report of a randomized control trial. Fam Cancer 12(3):537\u2013546. https:\/\/doi.org\/10.1007\/s10689-013-9609-z","journal-title":"Fam Cancer"},{"key":"240_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/jgc4.1317","author":"M Underhill-Blazey","year":"2020","unstructured":"Underhill-Blazey M, Blonquist T, Chittenden A, Pozzar R, Nayak M, Lansang K, Hong F, Garber J, Stopfer J (2020) Informing models of cancer genetic care in the era of multigene panel testing with patient-led recommendations. J Genet Couns. https:\/\/doi.org\/10.1002\/jgc4.1317","journal-title":"J Genet Couns"},{"issue":"6","key":"240_CR22","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1037\/0278-6133.21.6.564","volume":"21","author":"D Cella","year":"2002","unstructured":"Cella D, Hughes C, Peterman A, Chang C-H, Peshkin BN, Schwartz MD, Wenzel L, Lemke A, Marcus AC, Lerman C (2002) A brief assessment of concerns associated with genetic testing for cancer: the multidimensional impact of cancer risk assessment (MICRA) questionnaire. Health Psychol 21(6):564\u2013572. https:\/\/doi.org\/10.1037\/0278-6133.21.6.564","journal-title":"Health Psychol"},{"issue":"8","key":"240_CR23","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/j.pec.2019.04.014","volume":"102","author":"M Underhill-Blazey","year":"2019","unstructured":"Underhill-Blazey M, Stopfer J, Chittenden A, Nayak MM, Lansang K, Lederman R, Garber J, Gundersen DA (2019) Development and testing of the KnowGene scale to assess general cancer genetic knowledge related to multigene panel testing. Patient Educ Couns 102(8):1558\u20131564. https:\/\/doi.org\/10.1016\/j.pec.2019.04.014","journal-title":"Patient Educ Couns"},{"issue":"9","key":"240_CR24","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"H-F Hsieh","year":"2005","unstructured":"Hsieh H-F, Shannon S (2005) Three approaches to qualitative content analysis. Qual Health Res 15(9):1277\u20131288. https:\/\/doi.org\/10.1177\/1049732305276687","journal-title":"Qual Health Res"},{"issue":"4","key":"240_CR25","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10689-015-9811-2","volume":"14","author":"M Bjornslett","year":"2015","unstructured":"Bjornslett M, Dahl AA, Sorebo O, Dorum A (2015) Psychological distress related to BRCA testing in ovarian cancer patients. Fam Cancer 14(4):495\u2013504. https:\/\/doi.org\/10.1007\/s10689-015-9811-2","journal-title":"Fam Cancer"},{"issue":"11","key":"240_CR26","doi-asserted-by":"publisher","first-page":"e007618","DOI":"10.1136\/bmjopen-2015-007618","volume":"5","author":"S Watts","year":"2015","unstructured":"Watts S, Prescott P, Mason J, McLeod N, Lewith G (2015) Depression and anxiety in ovarian cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open 5(11):e007618. https:\/\/doi.org\/10.1136\/bmjopen-2015-007618","journal-title":"BMJ Open"},{"issue":"6","key":"240_CR27","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1017\/S1478951515000127","volume":"13","author":"M Ozga","year":"2015","unstructured":"Ozga M, Aghajanian C, Myers-Virtue S, McDonnell G, Jhanwar S, Hichenberg S, Sulimanoff I (2015) A systematic review of ovarian cancer and fear of recurrence. Palliat Support Care 13(6):1771\u20131780. https:\/\/doi.org\/10.1017\/S1478951515000127","journal-title":"Palliat Support Care"},{"issue":"3","key":"240_CR28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ygyno.2015.03.057","volume":"137","author":"E Fox","year":"2015","unstructured":"Fox E, McCuaig J, Demsky R, Shuman C, Chitayat D, Maganti M, Murphy J, Rosen B, Ferguson S, Randall Armel S (2015) The sooner the better: genetic testing following ovarian cancer diagnosis. Gynecol Oncol 137(3):423\u2013429. https:\/\/doi.org\/10.1016\/j.ygyno.2015.03.057","journal-title":"Gynecol Oncol"},{"issue":"3","key":"240_CR29","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1188\/13.ONF.40-03AP","volume":"40","author":"M Gleeson","year":"2013","unstructured":"Gleeson M, Meiser B, Barlow-Stewart K, Trainer A, Tucker K, Watts K, Friedlander M, Kasparian N (2013) Communication and information needs of women diagnosed with ovarian cancer regarding treatment-focused genetic testing. Oncol Nurs Forum 40(3):275\u2013283. https:\/\/doi.org\/10.1188\/13.ONF.40-03AP","journal-title":"Oncol Nurs Forum"},{"issue":"9","key":"240_CR30","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/jnci\/djy015","volume":"110","author":"AR Bradbury","year":"2018","unstructured":"Bradbury AR, Patrick-Miller LJ, Egleston BL, Hall MJ, Domchek SM, Daly MB, Ganschow P, Grana G, Olopade OI, Fetzer D, Brandt A, Chambers R, Clark DF, Forman A, Gaber R, Gulden C, Horte J, Long JM, Lucas T, Madaan S, Mattie K, McKenna D, Montgomery S, Nielsen S, Powers J, Rainey K, Rybak C, Savage M, Seelaus C, Stoll J, Stopfer JE, Yao XS (2018) Randomized noninferiority trial of telephone vs in-person disclosure of germline cancer genetic test results. J Natl Cancer Inst 110(9):985\u2013993. https:\/\/doi.org\/10.1093\/jnci\/djy015","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"240_CR31","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s10897-015-9887-8","volume":"25","author":"R O\u2019Shea","year":"2016","unstructured":"O\u2019Shea R, Meany M, Carroll C, Cody N, Healy D, Green A, Lynch SA (2016) Predictive genetic testing and alternatives to face to face results disclosure: a retrospective review of patients preference for alternative modes of BRCA 1 and 2 results disclosure in the Republic of Ireland. J Genet Couns 25(3):422\u2013431. https:\/\/doi.org\/10.1007\/s10897-015-9887-8","journal-title":"J Genet Couns"},{"issue":"2","key":"240_CR32","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/cge.13474","volume":"95","author":"N Beri","year":"2019","unstructured":"Beri N, Patrick-Miller LJ, Egleston BL, Hall MJ, Domchek SM, Daly MB, Ganschow P, Grana G, Olopade OI, Fetzer D, Brandt A, Chambers R, Clark DF, Forman A, Gaber R, Gulden C, Horte J, Long J, Lucas T, Madaan S, Mattie K, McKenna D, Montgomery S, Nielsen S, Powers J, Rainey K, Rybak C, Savage M, Seelaus C, Stoll J, Stopfer JE, Yao XS, Bradbury AR (2019) Preferences for in-person disclosure: patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study. Clin Genet 95(2):293\u2013301. https:\/\/doi.org\/10.1111\/cge.13474","journal-title":"Clin Genet"},{"issue":"1","key":"240_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12687-014-0197-x","volume":"6","author":"S Ashida","year":"2015","unstructured":"Ashida S, Schafer EJ (2015) Family health information sharing among older adults: reaching more family members. J Commun Genet 6(1):17\u201327. https:\/\/doi.org\/10.1007\/s12687-014-0197-x","journal-title":"J Commun Genet"},{"issue":"1","key":"240_CR34","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ygyno.2019.01.024","volume":"153","author":"EM Hinchcliff","year":"2019","unstructured":"Hinchcliff EM, Bednar EM, Lu KH, Rauh-Hain JA (2019) Disparities in gynecologic cancer genetics evaluation. Gynecol Oncol 153(1):184\u2013191. https:\/\/doi.org\/10.1016\/j.ygyno.2019.01.024","journal-title":"Gynecol Oncol"},{"issue":"3","key":"240_CR35","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.ygyno.2017.10.004","volume":"147","author":"RA Pozzar","year":"2017","unstructured":"Pozzar RA, Berry DL (2017) Patient-centered research priorities in ovarian cancer: a systematic review of potential determinants of guideline care. Gynecol Oncol 147(3):714\u2013722. https:\/\/doi.org\/10.1016\/j.ygyno.2017.10.004","journal-title":"Gynecol Oncol"},{"issue":"1","key":"240_CR36","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ygyno.2019.01.019","volume":"153","author":"RI Vogel","year":"2019","unstructured":"Vogel RI, Niendorf K, Petzel S, Lee H, Teoh D, Blaes AH, Argenta P, Rivard C, Winterhoff B, Lee HY, Geller MA (2019) A patient-centered mobile health application to motivate use of genetic counseling among women with ovarian cancer: a pilot randomized controlled trial. Gynecol Oncol 153(1):100\u2013107. https:\/\/doi.org\/10.1016\/j.ygyno.2019.01.019","journal-title":"Gynecol Oncol"},{"issue":"7","key":"240_CR37","doi-asserted-by":"publisher","first-page":"e0200559","DOI":"10.1371\/journal.pone.0200559","volume":"13","author":"MM Tea","year":"2018","unstructured":"Tea MM, Tan YY, Staudigl C, Eibl B, Renz R, Asseryanis E, Berger A, Pfeiler G, Singer CF (2018) Improving comprehension of genetic counseling for hereditary breast and ovarian cancer clients with a visual tool. PLoS ONE 13(7):e0200559. https:\/\/doi.org\/10.1371\/journal.pone.0200559","journal-title":"PLoS ONE"},{"issue":"7","key":"240_CR38","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.socscimed.2005.02.001","volume":"61","author":"RM Epstein","year":"2005","unstructured":"Epstein RM, Franks P, Fiscella K, Shields CG, Meldrum SC, Kravitz RL, Duberstein PR (2005) Measuring patient-centered communication in patient-physician consultations: theoretical and practical issues. Soc Sci Med 61(7):1516\u20131528. https:\/\/doi.org\/10.1016\/j.socscimed.2005.02.001","journal-title":"Soc Sci Med"},{"issue":"1","key":"240_CR39","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ygyno.2019.07.026","volume":"155","author":"RD Littell","year":"2019","unstructured":"Littell RD, Kumar A, Einstein MH, Karam A, Bevis K (2019) Advanced communication: a critical component of high quality gynecologic cancer care. A Society of Gynecologic Oncology evidence based review and guide. Gynecol Oncol 155(1):161\u2013169. https:\/\/doi.org\/10.1016\/j.ygyno.2019.07.026","journal-title":"Gynecol Oncol"},{"issue":"4","key":"240_CR40","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s10897-010-9296-y","volume":"19","author":"K Chivers Seymour","year":"2010","unstructured":"Chivers Seymour K, Addington-Hall J, Lucassen AM, Foster CL (2010) What facilitates or impedes family communication following genetic testing for cancer risk? A systematic review and meta-synthesis of primary qualitative research. J Genet Couns 19(4):330\u2013342. https:\/\/doi.org\/10.1007\/s10897-010-9296-y","journal-title":"J Genet Couns"},{"key":"240_CR41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10689-004-7992-1","volume":"4","author":"I Mesters","year":"2005","unstructured":"Mesters I, Ausems M, Eichhorn S, Vasen H (2005) Informing one\u2019s family about genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a retrospective exploratory study. Fam Cancer 4:163\u2013167","journal-title":"Fam Cancer"},{"issue":"2","key":"240_CR42","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10689-015-9852-6","volume":"15","author":"KF Douma","year":"2016","unstructured":"Douma KF, Smets EM, Allain DC (2016) Non-genetic health professionals\u2019 attitude towards, knowledge of and skills in discussing and ordering genetic testing for hereditary cancer. Fam Cancer 15(2):341\u2013350. https:\/\/doi.org\/10.1007\/s10689-015-9852-6","journal-title":"Fam Cancer"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-021-00240-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-021-00240-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-021-00240-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T11:31:09Z","timestamp":1643369469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10689-021-00240-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,10]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["240"],"URL":"https:\/\/doi.org\/10.1007\/s10689-021-00240-6","relation":{},"ISSN":["1389-9600","1573-7292"],"issn-type":[{"value":"1389-9600","type":"print"},{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,10]]},"assertion":[{"value":"19 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Jill E. Stopfer reports personal fees from Astra Zeneca. Rachel A. Pozzar, Fangxin Hong, Niya Xiong, Manan M. Nayak, and Meghan Underhill-Blazey have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Dana-Farber\/Harvard Cancer Center Institutional Review Board approved the study protocol.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}